LEADER 04039nam 2201165z- 450 001 9910566469403321 005 20231214133348.0 035 $a(CKB)5680000000037686 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81005 035 $a(EXLCZ)995680000000037686 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDiagnosis, Treatment and Prevention of Age-Related Macular Degeneration 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (246 p.) 311 $a3-0365-3930-1 311 $a3-0365-3929-8 330 $aIn this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients? quality of life. 606 $aMedicine$2bicssc 610 $aaflibercept monotherapy 610 $apolypoidal choroidal vasculopathy 610 $aneovascular age-related macular degeneration 610 $agood baseline visual acuity 610 $aForeseeHome AMD Monitoring SystemŪ 610 $aAREDS2-HOME study 610 $aage-related macular degeneration 610 $aexudation 610 $aoptical coherence tomography angiography 610 $aanti-vascular endothelial growth factor 610 $abrolucizumab 610 $aepithelial tear 610 $aoptical coherence tomography 610 $aSorsby's fundus dystrophy 610 $aSorsby 610 $ahereditary retinal dystrophy 610 $achoroidal neovascularisation 610 $amacular neovascularization 610 $aanti-VEGF treatment 610 $along-term FU 610 $atreatment outcome 610 $aemerging treatment 610 $aneovascular age-related macular degeneration (nAMD) 610 $aVascular Endothelial Growth Factor (VEGF) 610 $acataract surgery 610 $aclinical trials 610 $areal-world evidence 610 $aAMD 610 $aoct-angiography 610 $afellow eye 610 $achoriocapillaris 610 $aquiescent macular neovascularization 610 $aranibizumab 610 $aaflibercept 610 $aanti-VEGF 610 $avisual acuity 610 $areading acuity 610 $adisease activity 610 $atreatment change 610 $atreat and extend 610 $aswitch therapy 610 $aretina 610 $achoroidal neovascularization 610 $aangiogenesis 610 $ameteorin 610 $atherapeutic innovation 610 $aprevention 610 $anutrients 610 $alifestyle 610 $atreatment-naive 610 $aanti-vascular endothelial growth factor 610 $acardiovascular risk factors 610 $aarterial hypertension 610 $amacula-off rhegmatogenous detachment 610 $asuperficial perifoveal capillary plexus 610 $aretinal deep perifoveal capillary plexus 610 $aidentification 610 $arisk 610 $aDelphi 610 $aSTARSŪ 610 $afood supplement 610 $abevacizumab 610 $ameta-analysis 610 $ameta-regression 610 $aage-related macular degeneration (AMD) 610 $acomparative therapies 610 $aeffectiveness 610 $aintravitreal anti-vascular endothelial growth factor 610 $atreat-and-extend 610 $apro re nata regimen 615 7$aMedicine 700 $aKodjikian$b Laurent$4edt$01326251 702 $aKodjikian$b Laurent$4oth 906 $aBOOK 912 $a9910566469403321 996 $aDiagnosis, Treatment and Prevention of Age-Related Macular Degeneration$93037217 997 $aUNINA